<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0111234413
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DYNASTAT 40 mg Powder And solvent for Solution For injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PARECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        177.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACIA UPJOHN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACIA UPJOHN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dynastat contains the active substance parecoxib.<strong> </strong>Dynastat is used for the short-term treatment of pain in adults after an operation. It is one of a family of medicines called COX-2 inhibitors (this is short for <em>cyclo-oxygenase-2 inhibitors</em>).&nbsp; Pain and swelling are sometimes caused by substances in the body called <em>prostaglandins</em>. Dynastat works by lowering the amount of these prostaglandins.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Do not take Dynastat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to parecoxib or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a serious allergic reaction (especially a serious skin reaction) to any medicines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an allergic reaction to a group of medicines called &ldquo;sulfonamides&rdquo; (e.g. some antibiotics used to treat infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you currently have a gastric or intestinal ulcer or bleeding in the stomach or gut</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an allergic reaction to acetylsalicylic acid (aspirin) or to other NSAIDs (e.g. ibuprofen) or to COX-2 inhibitors. Reactions might include wheezing (bronchospasm), badly blocked nose, itchy skin, rash or swelling of the face, lips or tongue, other allergic reactions or nasal polyps after taking these medicines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 6 months pregnant</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have inflammation of the intestines (ulcerative colitis or Crohn&rsquo;s disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are about to have heart surgery or surgery on your arteries (including any coronary artery procedure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have established heart disease and /or cerebrovascular disease e.g. if you have had a heart attack, stroke, mini-stroke (TIA) or blockages to blood vessels to the heart or brain or an operation to clear or bypass blockages<em> </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had problems with your blood circulation (peripheral arterial disease)</p><p>&nbsp;</p><p>If any of these applies to you, you will not be given the injection.<strong> Tell your doctor or nurse immediately.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>Do not use Dynastat</strong> if you currently have a gastric or intestinal ulcer or gastrointestinal bleeding</p><p>&nbsp;</p><p><strong>Do not use Dynastat</strong> if you have severe liver disease</p><p>&nbsp;</p><p>Talk to your doctor or nurse before using Dynastat:</p><p>&nbsp;</p><p>&sect;&nbsp;&nbsp;&nbsp; If you have previously had an ulcer, bleeding or perforation of the gastrointestinal tract</p><p>&sect;&nbsp;&nbsp;&nbsp; If you have had a skin reaction (e.g. a rash, hives, welts, blisters, red streaks) with any medicine</p><p>&sect;&nbsp;&nbsp;&nbsp; If you are taking acetylsalicylic acid (aspirin) or other NSAIDs (e.g. ibuprofen)</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you smoke or drink alcohol</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you have diabetes</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you have angina, blood clots, high blood pressure or raised cholesterol</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you are taking antiplatelet therapies</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you have fluid retention (oedema)</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you have liver or kidney disease.</p><p>&sect;&nbsp;&nbsp;&nbsp; If you &nbsp;are dehydrated &ndash; this may happen if you have had diarrhoea or have been vomiting (being sick) or unable to drink fluids</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you have an infection as it may hide a fever (which is a sign of infection)</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you use medicines to reduce blood clotting (e.g. warfarin/warfarin like anticoagulants or novel oral anti-clotting medicines, e.g. apixaban, dabigatran, and rivaroxaban)</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you use medicines called corticosteroids (e.g. prednisone)</p><p>&sect;&nbsp;&nbsp;&nbsp; If &nbsp;you use a class of medicines used to treat depression called selective serotonin re-uptake inhibitors (e.g. sertraline)</p><p>&nbsp;</p><p>Dynastat can lead to an increase in blood pressure or worsening of existing high blood pressure which may result in an increase in side effects associated with heart conditions. Your doctor may want to monitor your blood pressure during treatment with Dynastat.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Children and adolescents under the age of 18 should not be given Dynastat.</p><p>&nbsp;</p><p>Potentially life-threatening skin rashes may occur with the use of Dynastat and treatment should be discontinued at the first appearance of skin rash, blistering and peeling of the skin, mucosal lesions, or any other sign of hypersensitivity. If you develop a rash, other skin, or mucosal (such as inside of cheeks or lips) signs and symptoms, seek immediate advice from a doctor and tell them that you are taking this medicine.</p><p>&nbsp;</p><p><strong>Other medicines and Dynastat </strong></p><p>Tell your doctor or nurse if<strong> </strong>you are taking, have recently taken or might take any other medicines. Medicines can sometimes interfere with each other.&nbsp; Your doctor may reduce the dose of Dynastat or other medicines, or you may need to take a different medicine.&nbsp; It&rsquo;s especially important to mention:</p><p>&nbsp;</p><p>&sect;&nbsp; Acetylsalicylic acid (aspirin) or other anti-inflammatory medicines</p><p>&sect;&nbsp; Fluconazole<strong> </strong>&ndash; used for fungal infections</p><p>&sect;&nbsp; ACE inhibitors, Angiotensin-II inhibitors, beta blockers and diuretics &ndash; used for high blood pressure and heart conditions</p><p>&sect;&nbsp; Ciclosporin or Tacrolimus &ndash; used after transplants</p><p>&sect;&nbsp; Warfarin &ndash; or other warfarin like medicines used to prevent blood clots including newer medicines like apixaban, dabigatran, and rivaroxaban</p><p>&sect;&nbsp; Lithium &ndash; used to treat depression</p><p>&sect;&nbsp; Rifampicin &ndash; used for bacterial infections</p><p>&sect;&nbsp; Antiarrhythmics &ndash; used to treat an irregular heartbeat</p><p>&sect;&nbsp; Phenytoin or Carbamazepine &ndash; used for epilepsy</p><p>&sect;&nbsp; Methotrexate &ndash; used for rheumatoid arthritis and cancer</p><p>&sect;&nbsp; Diazepam &ndash; used for sedation and anxiety</p><p>&sect;&nbsp; Omeprazole &ndash; used for treating ulcers</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>&sect;&nbsp;&nbsp;&nbsp; Dynastat must not be used if you are in the last 3 months of pregnancy as it could harm your unborn child or cause problems at delivery. It can cause kidney and heart problems in your unborn baby. It may affect your and your baby&rsquo;s tendency to bleed and cause labour to be later or longer than expected. Dynastat should not be used during the first 6 months of pregnancy unless absolutely necessary and advised by your doctor. If you need treatment during this period or while you are trying to get pregnant, the lowest dose for the shortest time possible should be used. If used for more than a few days from 20 weeks of pregnancy onward, Dynastat can cause kidney problems in your unborn baby that may lead to low levels of amniotic fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the heart of the baby. If you need treatment for longer than a few days, your doctor may recommend additional monitoring.</p><p>&sect;&nbsp;&nbsp;&nbsp; <strong>If you are breast-feeding</strong>, you must not receive Dynastat, as a small amount of Dynastat will be transferred to your breast milk.</p><p>&sect;&nbsp;&nbsp;&nbsp; NSAIDs, including Dynastat, may make it more difficult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>If the injection makes you feel dizzy or tired, do not drive or use machines until you feel better again.</p><p>&nbsp;</p><p><strong>Dynastat contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dynastat will be given to you by a doctor or nurse. They will dissolve the powder before giving you the injection, and will inject the solution into a vein or a muscle. The injection may be given rapidly and directly into a vein or into an existing intravenous line (a thin tube running into a vein), or it can be given slowly and deeply into a muscle. You will only be given Dynastat for short periods, and only for pain relief.</p><p>&nbsp;</p><p><strong>The usual dose to start with is 40 mg.</strong></p><p>You may be given another dose &ndash; either 20 mg or 40 mg &ndash; 6 to 12 hours after the first one.<br /><strong>You will not be given more than 80 mg in 24 hours.</strong></p><p>&nbsp;</p><p><strong>Some people may be given lower doses: </strong></p><p>&sect;&nbsp;&nbsp;&nbsp; People with liver problems</p><p>&sect;&nbsp;&nbsp;&nbsp; People with severe kidney problems</p><p>&sect;&nbsp;&nbsp;&nbsp; Patients over 65 who weigh less than 50 kg</p><p>&sect;&nbsp;&nbsp;&nbsp; People taking fluconazole.</p><p>&nbsp;</p><p><strong>If Dynastat is used with strong pain killers (called opioid analgesics) such as morphine</strong> the dose of Dynastat will be the same as explained above.</p><p>&nbsp;</p><p><strong>If you are given more Dynastat than you should,</strong> you may experience side effects that have been reported with recommended doses.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop taking Dynastat and tell your doctor immediately:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you develop a rash or ulceration in any part of your body (e.g. skin, mouth, eyes, face, lips or tongue), or develop any other signs of an allergic reaction such as skin rash, swelling of the face, lips or tongue which may cause wheezing, difficulty breathing, or swallowing &ndash; this occurs <strong>rarely</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have blistering or peeling of the skin - this occurs <strong>rarely</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the onset of skin reactions can occur at any time but most often occur in the first month of treatment; the reported rate of these events appears to be greater for valdecoxib, a medicine related to parecoxib, as compared to other COX-2 inhibitors</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have jaundice (your skin or the whites of your eyes appear yellow)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any signs of bleeding in the stomach or intestine, such as passing a black or blood-stained bowel movement or vomiting blood</p><p><strong>&nbsp;</strong></p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>&sect;&nbsp; Nausea (feeling sick)</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>&sect;&nbsp; Change in your blood pressure (up or down)</p><p>&sect;&nbsp; You may get back pain</p><p>&sect;&nbsp; Ankles, legs and feet may swell (fluid retention)</p><p>&sect;&nbsp; You may feel numb &ndash; your skin may lose sensitivity to pain and touch</p><p>&sect;&nbsp; You may get vomiting, stomach ache, indigestion, constipation, bloating and wind</p><p>&sect;&nbsp; Tests may show abnormal kidney function</p><p>&sect;&nbsp; You may feel agitated or find it hard to sleep</p><p>&sect;&nbsp; Dizziness</p><p>&sect;&nbsp; There is a risk of anaemia - changes in red blood cells after an operation that may cause fatigue and breathlessness</p><p>&sect;&nbsp; You may get a sore throat or difficulty breathing (shortness of breath)</p><p>&sect;&nbsp; Your skin may be itchy</p><p>&sect;&nbsp; You may pass less urine than usual</p><p>&sect;&nbsp; Dry socket (inflammation and pain after a tooth extraction)</p><p>&sect;&nbsp; Increased sweating</p><p>&sect;&nbsp; Low levels of potassium in blood test results</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&sect;&nbsp; Heart attack</p><p>&sect;&nbsp; There is a risk of cerebrovascular disease e.g. stroke, or transient ischaemic attack (transient reduced blood flow to the brain)/mini-stroke or angina, or blockages to blood vessels to the heart or brain</p><p>&sect;&nbsp; Blood clot in the lungs</p><p>&sect;&nbsp; Worsening of high blood pressure</p><p>&sect;&nbsp; Ulcers in the digestive system, chronic stomach acid reflux</p><p>&sect;&nbsp; The heart may beat more slowly</p><p>&sect;&nbsp; Low blood pressure on standing</p><p>&sect;&nbsp; Blood tests may show abnormal liver function</p><p>&sect;&nbsp; You may bruise easily due to a low blood platelet count</p><p>&sect;&nbsp; Surgical wounds may become infected, abnormal discharge from surgical wounds</p><p>&sect;&nbsp; Skin discolouration or bruising</p><p>&sect;&nbsp; Complications with skin healing after operations</p><p>&sect;&nbsp; High sugar levels in blood tests</p><p>&sect;&nbsp; Injection site pain or injection site reaction</p><p>&sect;&nbsp; Rash, or raised itchy rash (hives)</p><p>&sect;&nbsp; Anorexia (loss of appetite)</p><p>&sect;&nbsp; Joint pain</p><p>&sect;&nbsp; High levels of blood enzymes in blood tests that indicate injury or stress to the heart, the brain, or muscle tissue</p><p>&sect;&nbsp; Dry mouth</p><p>&sect;&nbsp; Muscle weakness</p><p>&sect;&nbsp; Ear ache</p><p>&sect;&nbsp; Unusual abdominal sounds</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people</strong></p><p>&sect;&nbsp; Rash or ulceration in any part of your body (e.g. skin, mouth, eyes, face, lips or tongue), or any other signs of allergic reactions such as skin rash, swelling of the face, lips and tongue, wheezing, difficulty breathing or swallowing (potentially fatal)</p><p>&sect;&nbsp; Swelling, blistering or peeling of the skin</p><p>&sect;&nbsp; Acute kidney failure</p><p>&sect;&nbsp; Hepatitis (inflamed liver)</p><p>&sect;&nbsp; Inflammation of the gullet (oesophagus)</p><p>&sect;&nbsp; Inflammation of the pancreas (can lead to stomach pain)</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&sect;&nbsp; Collapse due to severe low blood pressure&nbsp;</p><p>&sect;&nbsp; Heart failure</p><p>&sect;&nbsp; Kidney failure</p><p>&sect;&nbsp; Racing or irregularity of the heartbeat</p><p>&sect;&nbsp; Breathlessness</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p><p>&nbsp;</p><p>Store below 30&deg;C, do not refrigerate or freeze.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the vial label after Exp. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>It is recommended that Dynastat is used as soon as possible after it is mixed with solvent, although it may be stored if the instructions at the end of the leaflet are strictly followed. The injection solution should be a clear colourless liquid.<strong> If there are particles </strong>in the injection solution or if either the powder or solution is discoloured, the solution will not be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is parecoxib (as parecoxib sodium). &nbsp;Each vial contains 40 mg parecoxib, as 42.36 mg parecoxib sodium.&nbsp; When reconstituted with 2 ml solvent, provides 20 mg/ml of parecoxib. When reconstituted in sodium chloride 9 mg/ml (0.9%) solution, Dynastat contains approximately 0.44 mEq of sodium per vial.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><em>Powder</em></p><p>Disodium hydrogen phosphate</p><p>Phosphoric acid and/or sodium hydroxide (for pH adjustment).</p><p>&nbsp;</p><p>Solvent</p><p>Sodium chloride</p><p>Hydrochloric acid or sodium hydroxide (for pH adjustment)</p><p>Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Dynastat is available as a white to off-white powder.
	The powder is contained in colourless glass vials (5 ml) with a stopper, sealed with a purple flip-off cap on the aluminium overseal.
	The solvent is contained in colourless neutral glass ampoules (2 ml).
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder: &nbsp;</strong>Pfizer Europe MA EEIG, &nbsp;</p><p>Boulevard de la Plaine 17</p><p>1050 Bruxelles, Belgium</p><p>&nbsp;</p><p><strong>Manufacturing and primary packaging site:</strong></p><p>Pharmacia &amp; Upjohn Company LLC</p><p>Kalamazoo, USA</p><p>&nbsp;</p><p><strong>Secondary packaging and Release:</strong></p><p>Pfizer Manufacturing Belgium NV, Puurs-Sint-Amands, Belgium</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:402.85pt;
 height:248.9pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--><br /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:466.7pt;
 height:183.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ديناستات على المادة الفعالة باريكوكسيب.<strong> </strong>يستخدم ديناستات للعلاج قصير الأمد لألم ما بعد العمليات لدى البالغين. ينتمي هذا الدواء لمجموعة من الأدوية تسمى مثبطات COX-2 (وهو اختصار لعبارة <em>مثبطات إنزيم سيكلو-أوكسيجيناز-</em><em>۲</em>). أحيانًا ما يحدث الألم والتورم بسبب مواد في الجسم تُدعى <em>البروستاغلاندينات</em>. يعمل ديناستات على خفض كمية هذه البروستاغلاندينات في الجسم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">موانع استعمال ديناستات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه باريكوكسيب أو أي مكون آخر من مكونات هذا الدواء (المدرجة بالقسم ٦)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من تفاعل حساسية خطير (وخصوصًا التفاعل الجلدي الخطير) تجاه أي نوع من الأدوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بتفاعل حساسية تجاه مجموعة من الأدوية تُدعى &quot;السلفوناميدات&quot; (كبعض المضادات الحيوية المستخدمة لعلاج العدوى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا من قرحة معدية أو معوية أو نزيف بالمعدة أو الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من تفاعل حساسية تجاه حمض الأسيتيل ساليسيليك (أسبرين) أو تجاه مضادات الالتهاب غير الستيرويدية (NSAID) الأخرى (مثل إيبوبروفين) أو لمثبطات COX-2. قد تشتمل التفاعلات على الأزيز (التشنج القصبي)، أو الانسداد الشديد للأنف، أو حكة بالجلد، أو طفح جلدي أو تورم في الوجه أو الشفتين أو اللسان، أو تفاعلات حساسية أخرى أو سلائل أنفية بعد تناول هذه الأدوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملًا ومضى من حملك ما يزيد عن ٦ أشهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ترضعين رضاعة طبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد بالكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب في الأمعاء (التهاب القولون التقرحي أو داء كرون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على وشك إجراء جراحة بالقلب أو الشرايين (بما في ذلك أي إجراء بالشرايين التاجية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض قلبي و/أو مرض دماغي وعائي مؤكد مثل أن تكون قد أصبت بأزمة قلبية أو سكتة دماغية أو سكتة دماغية صغيرة (نوبة إقفارية عابرة (TIA)) أو انسداد الأوعية الدموية للقلب أو الدماغ أو خضعت لعملية لإزالة أو تجاوز الانسدادات<em> </em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو عانيت من قبل من مشكلات في الدورة الدموية (مرض الشرايين الطرفية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، فلن يتم إعطاؤك الحقن.<strong> أخبر طبيبك أو الممرضة على الفور.</strong></p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ديناستات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم ديناستات</strong> إذا كنت تعاني حاليًا من قرحة معدية أو معوية أو نزيف معدي معوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم ديناستات</strong> إذا كنت تعاني من مرض كبدي شديد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشر طبيبك أو الممرضة قبل استخدام ديناستات:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا سبق أن عانيت من القرحة أو النزيف أو الانثقاب بالقناة المعدية المعوية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن عانيت من تفاعل جلدي (مثل، طفح جلدي، شرى، انتبارات، بثور، أخاديد حمراء) مع أي دواء</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حمض الأسيتيل ساليسيليك (أسبرين) أو مضادات الالتهاب غير الستيرويدية الأخرى (مثل إيبوبروفين)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تدخن أو تتناول الكحوليات</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السكري</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الذبحة أو جلطات الدم أو ضغط الدم المرتفع أو ارتفاع نسبة الكوليسترول</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول علاجات مضادة لتكتل الصفيحات الدموية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من احتباس السوائل (التورم)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالكبد أو بالكلى.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالجفاف &ndash; قد يحدث هذا إذا كنت تعاني من الإسهال أو القيء (التقيؤ) أو كنت غير قادر على شرب السوائل</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى حيث أنه قد يخفي إصابتك بالحمى (وهي علامة من علامات العدوى)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية لتقليل تجلط الدم (مثل وارفارين/مضادات التجلط الشبيهة بوارفارين أو مضادات التجلط الحديثة التي تؤخذ عن طريق الفم مثل أبيكسابان، ودابيجاتران، وريفاروكسابان)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية تسمى الستيرويدات القشرية (مثل بريدنيزون)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم فئة من الأدوية تستخدم لعلاج الاكتئاب تسمى مثبطات إعادة امتصاص السيروتونين الانتقائية (مثل سيرترالين)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي ديناستات إلى ارتفاع في ضغط الدم أو تفاقم حالة ضغط الدم المرتفع الموجودة بالفعل مما قد ينتج عنه زيادة في الآثار الجانبية المرتبطة بحالات القلب. قد يرغب طبيبك في مراقبة ضغط دمك أثناء العلاج بديناستات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">ينبغي ألا يتلقى الأطفال والمراهقون أقل من ۱۸ عامًا ديناستات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث الطفح الجلدي الذي قد يكون مهددًا للحياة عند استخدام ديناستات وينبغي إيقاف العلاج بمجرد ظهور طفح جلدي، أو تبثر الجلد وتقشره، أو آفات الأغشية المخاطية، أو أي علامة أخرى من علامات فرط الحساسية. استشر الطبيب على الفور وأخبره أنك تتناول هذا الدواء، وذلك إذا ظهر عليك طفح جلدي، أو علامات وأعراض أخرى على الجلد أو في الأنسجة المخاطية (مثل الخدين أو الشفتين من الداخل).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. قد تتداخل الأدوية في بعض الأحيان مع بعضها البعض. قد يقرر طبيبك تقليل جرعة ديناستات أو الأدوية الأخرى أو قد تكون بحاجة إلى تناول دواء مختلف. من المهم جدًا أن تذكر:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليسيليك (أسبرين) أو الأدوية الأخرى المضادة للالتهاب</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول &ndash; يستخدم للعدوى الفطرية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثبطات الأنزيم المُحول للأنجيوتنسين (ACE) ومثبطات الأنجيوتنسين II ومحصرات البيتا ومدرات البول - تستخدم لعلاج ضغط الدم المرتفع وحالات القلب</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين أو تاكروليموس - تستخدم بعد عمليات زراعة الأعضاء</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين - أو الأدوية الأخرى المشابهة لوارفارين المستخدمة لمنع تكون جلطات الدم بما في ذلك الأدوية الجديدة مثل أبيكسابان، ودابيجاتران، وريفاروكسابان</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم - يستخدم لعلاج الاكتئاب</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين - يستخدم لعلاج العدوى البكتيرية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات اضطراب ضربات القلب - تستخدم لعلاج عدم انتظام ضربات القلب</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين أو كربامازيبين - يستخدم لعلاج الصرع</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات - يستخدم لعلاج التهاب المفاصل الروماتويدي والسرطان</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديازيبام &ndash; يستخدم للتهدئة وعلاج القلق</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوميبرازول &ndash; يستخدم لعلاج القرح</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام ديناستات إذا كنتِ في آخر ٣ أشهر من الحمل لأنه قد يضر بجنينكِ أو قد يسبب مشكلات في أثناء الولادة. ويمكن أيضًا أن يسبب مشكلات في الكُلى والقلب لدى الجنين. وقد يؤثر في زيادة القابلية للنزيف لديكِ ولدى طفلكِ ويُسبب تأخر المخاض أو إطالة مدته عن المتوقع. لا ينبغي استخدام ديناستات في أثناء أول ٦ أشهر من الحمل ما لم يكن ذلك ضروريًا للغاية وبناءً على مشورة طبيبكِ. إذا احتجتِ إلى علاج خلال هذه الفترة أو في أثناء محاولتكِ الحمل، ينبغي استخدام أقل جرعة لأقصر فترة ممكنة. إذا تم استخدام ديناستات لأكثر من بضعة أيام بعد ٢٠ أسبوعًا من الحمل فصاعدًا، فقد يسبب مشكلات في الكلى لدى الجنين مما قد يؤدي إلى انخفاض مستويات السائل السلوي المحيط بالجنين (قلة السائل السلوي) أو تضييق أحد الأوعية الدموية (القناة الشريانية) في قلب الطفل. إذا احتجتِ إلى علاج لأكثر من بضعة أيام، فقد يوصي طبيبكِ بمراقبة إضافية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ ترضعين طفلك رضاعة طبيعية</strong>، يجب ألا تتلقي ديناستات، حيث ستنتقل كمية قليلة من ديناستات إلى لبن الثدي.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تجعل مضادات الالتهاب غير الستيرويدية، بما في ذلك ديناستات، إمكانية الحمل أكثر صعوبة. ينبغي عليكِ إبلاغ طبيبك إذا كنتِ تخططين للحمل أو إذا كنتِ تواجهين مشكلات في حدوث الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملا أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملا أو تخططين للحمل، يجب استشارة طبيبك أو الممرضة قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ديناستات على القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا كان الحقن يجعلك تشعر بالدوار أو التعب، فلا تقم بقيادة السيارة أو استخدام الآلات حتى تشعر بالتحسن مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات ديناستات</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من واحد مليمول من الصوديوم (۲۳ ملجم) في كل مل، وهذا يعني أنه إلى حد كبير &quot;خال من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك ديناستات من قبل الطبيب أو الممرضة. سيقوم الطبيب أو الممرضة بإذابة المسحوق قبل إعطائك الحقن ثم حقنك بالمحلول في أحد الأوردة أو العضلات. قد يتم إعطاء الحقن بسرعة في الوريد مباشرة أو في خط وريدي موصل بالفعل (أنبوب رفيع يصل للوريد)، أو يمكن إعطاؤها ببطء وبعمق في عضلة. لن يتم إعطاؤك ديناستات إلا لفترات قصيرة ولتسكين الآلام فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يبلغ مقدار جرعة البدء المعتادة ٤</strong><strong>۰</strong><strong> ملجم.</strong></p><p dir="RTL">قد يتم إعطاؤك جرعة أخرى - إما ۲۰ ملجم أو ٤۰ ملجم - بعد ٦ إلى ۱۲ ساعة من الجرعة الأولى.<br /><strong>لن يتم إعطاؤك أكثر من </strong><strong>۸۰</strong><strong> ملجم في </strong><strong>۲</strong><strong>٤ ساعة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يتم إعطاء جرعات أقل لبعض الأشخاص مثل: </strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين يعانون من مشكلات بالكبد</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين يعانون من مشكلات شديدة بالكلى</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يزيد عمرهم عن ٦٥ عامًا ويقل وزنهم عن ٥۰ كلجم</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين يتلقون فلوكونازول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدام ديناستات مع مسكنات قوية للآلام (تسمى مُسكنات الألم الأفيونية) مثل مورفين</strong> فستكون جرعة ديناستات مماثلة لما تم توضيحه أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من</strong> <strong>ديناستات</strong></p><p dir="RTL"><strong>في حالة إعطاؤك جرعة ديناستات أكبر مما ينبغي</strong> فقد تُصاب بآثار جانبية تم الإبلاغ عن حدوثها مع الجرعات المُوصى بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، يمكنك سؤال طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن استخدام ديناستات وأخبر طبيبك فورًا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة ظهور طفح أو تقرح في أي جزء من أجزاء جسمك (مثل الجلد، أو الفم، أو العينين، أو الوجه، أو الشفتين، أو اللسان)، أو ظهور أي علامة أخرى من علامات تفاعلات الحساسية مثل الطفح الجلدي أو تورم الوجه، أو الشفتين، أو اللسان مما قد يسبب أزيزًا، وصعوبة في التنفس أو البلع - وذلك <strong>نادر الحدوث</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة ظهور تبثر أو تقشير في الجلد - وذلك <strong>نادر الحدوث</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تبدأ التفاعلات الجلدية في الظهور في أي وقت ولكن يحدث هذا في أغلب الأوقات في الشهر الأول من العلاج، لذلك يبدو أن معدل ظهور هذه الأعراض يكون أكبر بالنسبة لفالديكوكسيب، دواء مرتبط بباريكوكسيب، مقارنة بمثبطات COX-2 الأخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة إصابتك باليرقان (اصفرار في جلدك أو في بياض عينيك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي علامات على حدوث نزيف في المعدة أو الأمعاء، مثل تغوط براز أسود أو ملطخ بالدم أو تقيؤ دم</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل </strong><strong>۱۰</strong><strong> أشخاص</strong></p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الغثيان (الشعور بالرغبة في التقيؤ)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل </strong><strong>۱۰</strong><strong> أشخاص</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في ضغط دمك (قد يزيد أو ينخفض)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر بألم الظهر</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتورم الكاحلان أو الساقان أو القدمان (احتباس السوائل)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر بالخدر - قد يفقد جلدك الإحساس بالألم واللمس</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتعرض للقيء، وألم المعدة، وسوء الهضم، والإمساك، والانتفاخ، والغازات</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تظهر الفحوصات وجود وظائف كلى غير طبيعية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر بالتهيج أو تجد صعوبة في النوم</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توجد خطورة الإصابة بفقر الدم - تغيرات في خلايا الدم الحمراء بعد إجراء عملية مما قد يسبب الإرهاق أو عسر التنفس</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب باحتقان الحلق أو صعوبة في التنفس (ضيق التنفس)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر بحكة في الجلد</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتبول كمية أقل من المعتاد</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف تجويف السن المخلوع (التهاب وآلام بعد اقتلاع السن)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة العرق</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم في نتائج فحوصات الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل </strong><strong>۱۰۰</strong><strong> شخص</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توجد خطورة للإصابة بأمراض دماغية وعائية مثل السكتة الدماغية أو نوبة إقفارية عابرة (انخفاض عابر في تدفق الدم للدماغ)/سكتة دماغية صغيرة أو ذبحة أو انسداد في الأوعية الدموية المتجهة إلى القلب أو الدماغ</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دم في الرئتين</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالة ضغط الدم المرتفع</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح في الجهاز الهضمي وارتجاع حمضي مزمن بالمعدة</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يصبح معدل ضربات القلب أبطأ</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم عند الوقوف</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تظهر فحوصات الدم وظائف كبد غير طبيعية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث لك كدمات بسهولة نتيجة انخفاض تعداد الصفيحات الدموية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث عدوى بالجروح الناتجة عن العمليات الجراحية مع إفرازات غير طبيعية من هذه الجروح</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تغير لون الجلد أو تكدمه</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>مضاعفات التئام الجلد بعد العمليات</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتفاع مستويات السكر في فحوصات الدم</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الشعور بالآلام في موضع الحقن أو تفاعل موضع الحقن</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>حدوث طفح جلدي أو طفح جلدي بارز مسبب للحكة (شرى)</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قهم (فقدان الشهية)</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم المفاصل</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتفاع مستويات إنزيمات الدم في فحوصات الدم مما يدل على وجود إصابة أو إجهاد على القلب أو الدماغ أو النسيج العضلي</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>جفاف الفم</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضعف العضلات</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم الأذن</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أصوات غير طبيعية في البطن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: قد تصيب ما يصل إلى شخص واحد بين كل </strong><strong>۱۰۰۰</strong><strong> شخص</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو تقرح في أي جزء من أجزاء الجسم (مثل الجلد، أو الفم، أو العينين، أو الوجه، أو الشفتين، أو اللسان)، أو أي علامة أخرى من علامات تفاعلات الحساسية مثل الطفح الجلدي، أو تورم الوجه والشفتين واللسان، أو الأزيز، أو صعوبة التنفس أو البلع (قد تكون هذه الأعراض مميتة)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجلد أو تقرحه أو تقشره</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى الحاد</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (كبد ملتهب)</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التهاب المريء</p><p>&nbsp;</p><p>&nbsp;<p dir="RTL"><strong>&nbsp;</strong></p></p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التهاب البنكرياس (يمكن أن يؤدي إلى حدوث ألم بالمعدة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير نسبة التكرار من البيانات المتاحة</strong></p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الدوار بسبب الانخفاض الشديد لضغط الدم</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فشل القلب</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فشل الكلى</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تسارع ضربات القلب أو عدم انتظامها</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عسر التنفس</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، فتحدث إلى طبيبك أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة لم يرد ذكرها في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><em>&nbsp;</em></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>الموقع الإلكتروني:https://ade.sfda.gov.sa/&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول </strong><strong>الخليج</strong><strong> الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:342px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في درجة حرارة اقل من&nbsp; ۳۰ درجة مئوية .لا يحفظ فى الثلاجة و لا يجمد.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى ملصق القارورة بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى باستخدام ديناستات بعد خلطه بالمذيب في أسرع وقت ممكن، على الرغم من أنه يمكن تخزينه إذا تم اتباع التعليمات الموجودة في آخر هذه النشرة بدقة. ينبغي أن يكون محلول الحقن سائلًا رائقًا شفافًا.<strong> في حالة وجود جسيمات</strong> في محلول الحقن أو في حالة تغير لون المسحوق أو المحلول، يجب عدم استخدام هذا المحلول.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي مادة باريكوكسيب (في صورة صوديوم باريكوكسيب). تحتوي كل قارورة على ٤۰ ملجم من باريكوكسيب، بما يعادل ٤۲,۳٦ ملجم من صوديوم باريكوكسيب. عند التحضير بـ۲ مل من المذيب، ينتج ۲۰ ملجم/مل من باريكوكسيب. عند التحضير بمحلول كلوريد الصوديوم ۹ ملجم/مل (۰,۹ ٪)، يحتوي ديناستات على ما يقرب من ۰,٤٤ مل مكافئ من الصوديوم لكل قارورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><em>المسحوق</em></p><p dir="RTL">فوسفات هيدروجين ثنائي الصوديوم</p><p dir="RTL">حمض الفوسفوريك و/أو هيدروكسيد الصوديوم (لتعديل درجة الحموضة).</p><p dir="RTL">&nbsp;</p><p><em>المذيب</em></p><p dir="RTL">كلوريد الصوديوم</p><p dir="RTL">حمض الهيدروكلوريك أو هيدروكسيد الصوديوم (لتعديل درجة الحموضة)</p><p dir="RTL">ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر ديناستات في صورة مسحوق أبيض أو أبيض مائل إلى الصفرة.</p><p dir="RTL">المسحوق معبأ في قوارير زجاجية عديمة اللون (٥ مل) مع سدادة محكمة الغلق بغطاء أرجواني يُفتح لأعلى على غلاف الإغلاق المصنوع من الألومنيوم.</p><p dir="RTL">المذيب معبأ في أمبولات عديمة اللون مصنوعة من الزجاج المتعادل (۲ مل).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة </strong><strong>التسويق</strong>:</p><p>Pfizer Europe MA EEIG,</p><p>Boulevard de la Plaine 17</p><p>1050 Bruxelles, Belgium</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة الصانعة</strong>:</p><p>Pharmacia &amp; Upjohn Company LLC</p><p>Kalamazoo, USA</p><p>&nbsp;</p><p dir="RTL"><strong>شركة التغليف والفسح النهائي</strong>:</p><p dir="RTL">Pfizer Manufacturing Belgium NV, Puurs-Sint-Amands, Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dynastat 40 mg powder and solvent for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder vial: Each vial contains 40 mg parecoxib (as 42.36 mg parecoxib sodium). After reconstitution, the concentration of parecoxib is 20 mg/ml. Each 2 ml of reconstituted powder contains 40 mg of parecoxib.

Excipient with known effect 
This medicinal product contains less than 1 mmol sodium (23 mg) per dose.

When reconstituted in sodium chloride 9 mg/ml (0.9%) solution, Dynastat contains approximately 0.44 mmol of sodium per vial.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection (powder for injection).
White to off-white powder.

Solvent: clear and colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the short-term treatment of postoperative pain in adults.</p><p>&nbsp;</p><p>The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is 40&nbsp;mg administered intravenously (IV) or intramuscularly (IM), followed every 6 to 12 hours by 20&nbsp;mg or 40&nbsp;mg as required, not to exceed 80&nbsp;mg/day.</p><p>&nbsp;</p><p>As the cardiovascular risk of COX-2 specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. There is limited clinical experience of treatment with Dynastat beyond three days (see section 5.1).</p><p>&nbsp;</p><p><u>Concomitant use with opioid analgesics</u></p><p>Opioid analgesics can be used concurrently with parecoxib, dosing as described in the paragraph above. In all clinical assessments parecoxib was administered at a fixed time interval whereas the opioids were administered on as needed basis.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>No dose adjustment is generally necessary in elderly patients (&ge;65 years). However, for elderly patients weighing less than 50&nbsp;kg, treatment should be initiated with half the usual recommended dose of Dynastat and reduce the maximum daily dose to 40&nbsp;mg (see section 5.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score &sup3;10), therefore its use is contraindicated in these patients (see sections 4.3 and 5.2). No dosage adjustment is generally necessary in patients with mild hepatic impairment (Child-Pugh score 5‑6). Dynastat should be introduced with caution and at half the usual recommended dose in patients with moderate hepatic impairment (Child-Pugh score 7-9) and the maximum daily dose should be reduced to 40&nbsp;mg.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In patients with<u> </u>severe renal impairment (creatinine clearance &lt;30&nbsp;ml/min.) or patients who may be predisposed to fluid retention, parecoxib should be initiated at the lowest recommended dose (20&nbsp;mg) and the patient&#39;s kidney function should be closely monitored (see sections 4.4 and 5.2). On the basis of pharmacokinetics, no dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance of 30-80&nbsp;ml/min.).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of parecoxib in children under 18&nbsp;years old have not been established. No data are available. Therefore, parecoxib is not recommended in these patients.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The IV bolus injection may be given rapidly and directly into a vein or into an existing IV line. The IM injection should be given slowly and deeply into the muscle. For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p><p>Precipitation may occur when Dynastat is combined in solution with other medicinal products and therefore Dynastat must not be mixed with any other medicinal product, either during reconstitution or injection.<em> </em>In those patients where the same IV line is to be used to inject another medicinal product, the line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility.</p><p><em>&nbsp;</em></p><p>After reconstitution with acceptable solvents, Dynastat may <strong>only</strong> be injected IV or IM, or into IV lines delivering the following:</p><p>&nbsp;</p><ul><li>sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection/infusion;</li><li>glucose 50&nbsp;mg/ml (5%) solution for infusion;</li><li>sodium chloride 4.5&nbsp;mg/ml (0.45%) and glucose 50&nbsp;mg/ml (5%) solution for injection/infusion; or</li><li>Ringer-Lactate solution for injection.</li></ul><p>&nbsp;</p><p>Injection into an IV line delivering glucose 50&nbsp;mg/ml (5%) in Ringer-Lactate solution for injection, or other IV fluids not listed above, is <strong>not</strong> recommended as this may cause precipitation from solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

History of previous serious allergic drug reaction of any type, especially cutaneous reactions such as Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome (DRESS syndrome), toxic epidermal necrolysis, erythema multiforme or patients with known hypersensitivity to sulfonamides (see sections 4.4 and 4.8).

Active peptic ulceration or gastrointestinal (GI) bleeding.

Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or nonsteroidal anti inflammatory drugs (NSAIDs) including COX-2 inhibitors.

The third trimester of pregnancy and breast-feeding (see sections 4.6 and 5.3).

Severe hepatic impairment (serum albumin <25 g/l or Child-Pugh score 10).

Inflammatory bowel disease.

Congestive heart failure (NYHA II-IV).

Treatment of post-operative pain following coronary artery bypass graft (CABG) surgery (see sections 4.8 and 5.1).

Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dynastat has been studied in dental, orthopaedic, gynaecologic (principally hysterectomy) and coronary artery bypass graft surgery. There is limited experience in other types of surgery, for example gastrointestinal or urological surgery (see section 5.1).</p><p>&nbsp;</p><p>Modes of administration other than IV or IM (e.g. intra-articular, intrathecal) have not been studied and should not be used.</p><p>&nbsp;</p><p>Because of the possibility for increased adverse reactions at higher doses of parecoxib, other COX‑2 inhibitors and NSAIDs, patients treated with parecoxib should be reviewed following dose increase and, in the absence of an increase in efficacy, other therapeutic options should be considered (see section&nbsp;4.2). There is limited clinical experience of treatment with Dynastat beyond three days (see section&nbsp;5.1).</p><p>&nbsp;</p><p>If, during treatment, patients deteriorate in any of the organ system functions described below, appropriate measures should be taken and discontinuation of parecoxib therapy should be considered.</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p>COX-2 inhibitors have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term. The exact magnitude of the risk associated with a single dose has not been determined, nor has the exact duration of therapy associated with increased risk.</p><p>&nbsp;</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with parecoxib after careful consideration (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p>Appropriate measures should be taken and discontinuation of parecoxib therapy should be considered if there is clinical evidence of deterioration in the condition of specific clinical symptoms in these patients. Dynastat has not been studied in cardiovascular revascularization procedures other than coronary artery bypass graft (CABG) procedures. Studies in types of surgery other than CABG procedures included patients with American Society of Anaesthesiology (ASA) Physical Status Class I-III only.</p><p>&nbsp;</p><p><u>Acetylsalicylic acid and other NSAIDs</u></p><p>COX-2 inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore, antiplatelet therapies should not be discontinued (see section 5.1). Caution should be exercised when co-administering Dynastat with warfarin and other oral anticoagulants (see section 4.5). The concomitant use of parecoxib with other non- acetylsalicylic acid NSAIDs should be avoided.</p><p>&nbsp;</p><p>Dynastat may mask fever and other signs of inflammation (see section 5.1). In isolated cases, an aggravation of soft tissue infections has been described in connection with the use of NSAIDs and in nonclinical studies with Dynastat (see section 5.3). Caution should be exercised with respect to monitoring the incision for signs of infection in surgical patients receiving Dynastat.</p><p><em>&nbsp;</em></p><p><u>Gastrointestinal</u></p><p>Upper gastrointestinal (GI) complications (perforations, ulcers or bleedings [PUBs]), some of them resulting in fatal outcome, have occurred in patients treated with parecoxib. Caution is advised in the treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding, or patients using acetylsalicylic acid concomitantly. The NSAIDs class is also associated with increased GI complications when co-administered with glucocorticoids, selective serotonin reuptake inhibitors, other antiplatelet drugs, other NSAIDs or patients ingesting alcohol. There is further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications), when parecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).</p><p>&nbsp;</p><p><u>Skin reactions</u></p><p>Serious skin reactions, including erythema multiforme, exfoliative dermatitis and Stevens‑Johnson syndrome (some of them fatal) have been reported through post-marketing surveillance in patients receiving parecoxib. Additionally, fatal reports of toxic epidermal necrolysis have been reported through post-marketing surveillance in patients receiving valdecoxib (the active metabolite of parecoxib) and cannot be ruled out for parecoxib (see section 4.8). Some NSAIDs and selective COX-&nbsp;2 inhibitors have been associated with an increased risk of generalized bullous fixed drug eruptions (GBFDE). DRESS syndrome may occur with parecoxib exposure based on other serious skin reactions reported with celecoxib and valdecoxib exposure. Patients appear to be at highest risk for these reactions early in the course of therapy; the onset of the reaction occurring in the majority of cases within the first month of treatment.</p><p>&nbsp;</p><p>Appropriate measures should be taken by physicians to monitor for any serious skin reactions with therapy, e.g. additional patient consultations. Patients should be advised to immediately report any emergent skin condition to their physician.</p><p>&nbsp;</p><p>Parecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Serious skin reactions are known to occur with NSAIDs including COX‑2 selective inhibitors as well as other medicinal products. However, the reported rate of serious skin events appears to be greater for valdecoxib (the active metabolite of parecoxib) as compared to other COX‑2 selective inhibitors. Patients with a history of sulfonamide allergy may be at greater risk of skin reactions (see section 4.3). Patients without a history of sulfonamide allergy may also be at risk for serious skin reactions.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity reactions (anaphylaxis and angioedema) have been reported in post-marketing experience with valdecoxib and parecoxib (see section 4.8). Some of these reactions have occurred in patients with a history of allergic-type reactions to sulfonamides (see section 4.3). Parecoxib should be discontinued at the first sign of hypersensitivity.</p><p>&nbsp;</p><p>Cases of severe hypotension shortly following parecoxib administration have been reported in post-marketing experience with parecoxib. Some of these cases have occurred without other signs of anaphylaxis. The physician should be prepared to treat severe hypotension.</p><p>&nbsp;</p><p><u>Fluid retention, oedema, renal</u></p><p>As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention and oedema have been observed in some patients taking parecoxib. Therefore, parecoxib should be used with caution in patients with compromised cardiac function, preexisting oedema, or other conditions predisposing to, or worsened by, fluid retention including those taking diuretic treatment or otherwise at risk of hypovolemia. If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of parecoxib should be taken.</p><p>&nbsp;</p><p>Acute renal failure has been reported through post-marketing surveillance in patients receiving parecoxib (see section 4.8). Since prostaglandin synthesis inhibition may result in deterioration of renal function and fluid retention, caution should be observed when administering Dynastat in patients with impaired renal function (see section 4.2) or hypertension, or in patients with compromised cardiac or hepatic function or other conditions predisposing to fluid retention.</p><p>&nbsp;</p><p>Caution should be used when initiating treatment with Dynastat in patients with dehydration. In this case, it is advisable to rehydrate patients first and then start therapy with Dynastat.</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>As with all NSAIDs, parecoxib can lead to the onset of new hypertension or worsening of pre‑existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Parecoxib should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of therapy with parecoxib and throughout the course of therapy. If blood pressure rises significantly, alternative treatment should be considered.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Dynastat should be used with caution in patients with moderate hepatic impairment (Child-Pugh score&nbsp;7-9) (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><u>Use with oral anticoagulants</u></p><p>The concomitant use of NSAIDs with oral anticoagulants increases the risk of bleeding. Oral anticoagulants include warfarin/coumarin-type and novel oral anticoagulants (e.g. apixaban, dabigatran, and rivaroxaban) (see section 4.5).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p>Anticoagulant therapy should be monitored, particularly during the first few days after initiating parecoxib therapy in patients receiving warfarin or other anticoagulants, since these patients have an increased risk of bleeding complications. Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with parecoxib is initiated or the dose of parecoxib is changed (see section 4.4).</p><p>&nbsp;</p><p>Dynastat had no effect on acetylsalicylic acid-mediated inhibition of platelet aggregation or bleeding times. Clinical trials indicate that Dynastat can be given with low dose acetylsalicylic acid (&pound;325&nbsp;mg). In the submitted studies, as with other NSAIDs, an increased risk of gastrointestinal ulceration or other gastrointestinal complications compared to use of parecoxib alone was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).</p><p>&nbsp;</p><p>Co-administration of parecoxib and heparin did not affect the pharmacodynamics of heparin (activated partial thromboplastin time) compared to heparin alone.</p><p>&nbsp;</p><p>Inhibition of prostaglandins by NSAIDs, including COX-2 inhibitors, may diminish the effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, beta-blockers and diuretics. This interaction should be given consideration in patients receiving parecoxib concomitantly with ACE-inhibitors, angiotensin II antagonists, beta-blockers and diuretics.</p><p>&nbsp;</p><p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX‑2 inhibitors, with ACE inhibitors or Angiotensin-II antagonists, may result in further deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</p><p>&nbsp;</p><p>Therefore, the concomitant administration of these drugs should be done with caution. Patients should be adequately hydrated and the need to monitor the renal function should be assessed at the beginning of the concomitant treatment and periodically thereafter.</p><p>&nbsp;</p><p>Co-administration of NSAIDs and ciclosporin or tacrolimus has been suggested to increase the nephrotoxic effect of ciclosporin and tacrolimus because of NSAID effects on renal prostaglandins. Renal function should be monitored when parecoxib and any of these medicinal products are co-administered.</p><p>&nbsp;</p><p>Dynastat may be co-administered with opioid analgesics. In clinical trials, the daily requirement for PRN opioids was significantly reduced when co-administered with parecoxib.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on the pharmacokinetics of parecoxib (or its active metabolite valdecoxib)</u></p><p>Parecoxib is rapidly hydrolysed to the active metabolite valdecoxib. In humans, studies demonstrated that valdecoxib metabolism is predominantly mediated via CYP3A4 and 2C9 isozymes.</p><p>&nbsp;</p><p>Plasma exposure (AUC and C<sub>max</sub>) to valdecoxib was increased (62% and 19%, respectively) when co-administered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of parecoxib should be reduced in those patients who are receiving fluconazole therapy.</p><p>&nbsp;</p><p>Plasma exposure (AUC and C<sub>max</sub>) to valdecoxib was increased (38% and 24%, respectively) when co-administered with ketoconazole (CYP3A4 inhibitor), however, a dosage adjustment should not generally be necessary for patients receiving ketoconazole.</p><p>&nbsp;</p><p>The effect of enzyme induction has not been studied. The metabolism of valdecoxib may increase when co-administered with enzyme inducers such as rifampicin, phenytoin, carbamazepine or dexamethasone.</p><p>&nbsp;</p><p><u>Effect of parecoxib (or its active metabolite valdecoxib) on the pharmacokinetics of other medicinal products</u></p><p>Treatment with valdecoxib (40 mg twice daily for 7 days) produced a 3-fold increase in plasma concentrations of dextromethorphan (CYP2D6 substrate). Therefore, caution should be observed when co-administering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).</p><p>&nbsp;</p><p>Plasma exposure of omeprazole (CYP 2C19 substrate) 40&nbsp;mg once daily was increased by 46% following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to valdecoxib was unaffected. These results indicate that although valdecoxib is not metabolised by CYP2C19, it may be an inhibitor of this isoenzyme. Therefore, caution should be observed when administering Dynastat with medicinal products known to be substrates of CYP2C19 (e.g. phenytoin, diazepam, or imipramine).</p><p><s>&nbsp;</s></p><p>In two pharmacokinetic interaction studies in rheumatoid arthritis patients receiving a stable weekly methotrexate dose (5-20&nbsp;mg/week, as a single oral or intramuscular dose), orally administered valdecoxib (10&nbsp;mg twice daily or 40&nbsp;mg twice daily) had little or no effect on the steady-state plasma concentrations of methotrexate. However caution is advised when methotrexate is administered concurrently with NSAIDs, because NSAID administration may result in increased plasma levels of methotrexate. Adequate monitoring of methotrexate-related toxicity should be considered when co-administering parecoxib and methotrexate.</p><p>&nbsp;</p><p>Co-administration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone. Lithium serum concentration should be monitored closely when initiating or changing parecoxib therapy in patients receiving lithium.</p><p>&nbsp;</p><p>Co-administration of valdecoxib with glibenclamide (CYP3A4 substrate) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glibenclamide.</p><p>&nbsp;</p><p><u>Injectable anaesthetics</u></p><p>Co-administration of IV parecoxib 40&nbsp;mg with propofol (CYP2C9 substrate) or midazolam (CYP3A4 substrate) did not affect either the pharmacokinetics (metabolism and exposure) or the pharmacodynamics (EEG effects, psychomotor tests and waking from sedation) of IV propofol or IV midazolam. Additionally, co-administration of valdecoxib had no clinically significant effect on the hepatic or intestinal CYP 3A4-mediated metabolism of orally administered midazolam. Administration of IV parecoxib 40&nbsp;mg had no significant effect on the pharmacokinetics of either IV fentanyl or IV alfentanil (CYP3A4 substrates).</p><p>&nbsp;</p><p><u>Inhalation anaesthetics</u></p><p>No formal interaction studies have been done. In surgery studies in which parecoxib was administered pre-operatively, no evidence of pharmacodynamic interaction was observed in patients receiving parecoxib and the inhalation anaesthetic agents nitrous oxide and isoflurane (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of parecoxib in pregnant women or during labour. However, inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of miscarriage after use of prostaglandin synthesis inhibitors in early pregnancy. In animals, administration of prostaglandin synthesis inhibitors, including parecoxib, has been shown to result in increased pre- and post‑implantation loss and embryo‑foetal lethality (see sections&nbsp;5.1 and 5.3). From the 20th week of pregnancy onward, parecoxib use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. In addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, during the first and second trimester of pregnancy, this medicine should not be given unless clearly necessary. If parecoxib is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure to parecoxib for several days from gestational week 20 onward. parecoxib should be discontinued if oligohydramnios or ductus arteriosus constriction are found.</p><p>&nbsp;</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:</p><ul><li>cardiopulmonary toxicity (premature constriction/closure of the ductus arteriosus and pulmonary hypertension);</li><li>renal dysfunction (see above);</li></ul><p>the mother and the neonate, at the end of pregnancy, to:</p><ul><li>possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses;</li><li>inhibition of uterine contractions resulting in delayed or prolonged labour.</li></ul><p>Consequently, parecoxib is contraindicated during the third trimester of pregnancy (see sections 4.3 and&nbsp;5.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Administration of a single dose of parecoxib to lactating women following caesarean section resulted in the transfer of a relatively small amount of parecoxib and its active metabolite valdecoxib into human milk, and this resulted in a low relative dose for the infant (approximately 1% of the weight‑adjusted maternal dose). Dynastat must not be administered to women who breast-feed (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The use of Dynastat, as with any medicinal product known to inhibit cyclooxygenase/prostaglandin synthesis, is not recommended in women attempting to conceive (see sections 4.3, 5.1 and 5.3).</p><p>&nbsp;</p><p>Based on the mechanism of action, the use of NSAIDs, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of NSAIDs, including Dynastat should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizzineess, vertigo or somnolence after receiving Dynastat should refrain from driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common adverse reaction for Dynastat is nausea. The most serious reactions occur uncommonly to rarely, and include cardiovascular events such as myocardial infarction and severe hypotension, as well as hypersensitivity events such as anaphylaxis, angioedema and severe skin reactions. Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse reactions such as: cardiovascular/thromboembolic events (including myocardial infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep surgical infections, and sternal wound healing complications.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions were reported for patients who received parecoxib (N=5,402) in 28&nbsp;placebo-controlled clinical trials. Reports from post-marketing experience have been listed as &ldquo;frequency not known&rdquo; because the respective frequencies cannot be estimated from the available data. Within each frequency grouping, adverse reactions are listed using MedDRA terminology and presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="5" style="vertical-align:top"><p><strong><u>Adverse Drug Reaction Frequency</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><em><u>Very Common </u></em><em>(</em><em>&sup3;</em><em>1/10)</em></p></td><td style="vertical-align:top"><p><em><u>Common</u></em></p><p><em>(</em><em>&sup3;</em><em>1/100 to &lt;1/10)</em></p></td><td style="vertical-align:top"><p><em><u>Uncommon</u></em></p><p><em>(</em><em>&sup3;</em><em>1/1000 to &lt;1/100)</em></p></td><td style="vertical-align:top"><p><em><u>Rare</u></em><em> (</em><em>&sup3;</em><em>1/10,000 to &lt;1/1000)</em></p></td><td style="vertical-align:top"><p><em><u>Not known</u></em></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><em><u>Infections and infestations</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pharyngitis, alveolar osteitis (dry socket)</p></td><td style="vertical-align:top"><p>Abnormal sternal serous wound drainage, wound infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Blood and lymphatic system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia postoperative</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Immune system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Metabolism and nutrition disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Hyperglycaemia, anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Psychiatric disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agitation, insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Nervous system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoaesthesia, dizziness</p></td><td style="vertical-align:top"><p>Cerebrovascular disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Ear and labyrinth disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Ear pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Cardiac disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction, bradycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Circulatory collapse,</p><p>congestive heart failure, tachycardia</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Vascular disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension, hypotension</p></td><td style="vertical-align:top"><p>Hypertension (aggravated), orthostatic hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Respiratory, thoracic and mediastinal disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Respiratory insufficiency</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Gastrointestinal disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain, vomiting, constipation, dyspepsia, flatulence</p></td><td style="vertical-align:top"><p>Gastroduodenal ulceration, gastrooesophageal reflux disease, dry mouth, gastrointestinal sounds abnormal</p></td><td style="vertical-align:top"><p>Pancreatitis, oesophagitis, oedema mouth (perioral swelling)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Skin and subcutaneous tissue disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus, hyperhidrosis</p></td><td style="vertical-align:top"><p>Ecchymosis, rash, urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome,</p><p>erythema multiforme,</p><p>exfoliative dermatitis</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Musculoskeletal and connective tissue disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Renal and urinary disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oliguria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal failure acute</p></td><td style="vertical-align:top"><p>Renal failure,</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>General disorders and administration site conditions</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Asthenia, injection site pain, injection site reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including anaphylaxis and angioedema</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Investigations</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Blood CPK increased, blood LDH increased, SGOT increased,</p><p>SGPT increased,</p><p>BUN increased.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em><u>Injury, poisoning and procedural complications</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Post procedural complication (skin)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>In post-marketing experience, toxic epidermal necrolysis has been reported in association with the use of valdecoxib, and cannot be ruled out for parecoxib (see section 4.4). In addition, the following rare, serious adverse reactions have been reported in association with the use of NSAIDs and cannot be ruled out for Dynastat: bronchospasm and hepatitis.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Centre (NPC).</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reporting of overdose with parecoxib has been associated with adverse reactions which have also been described with recommended doses of parecoxib.</p><p>&nbsp;</p><p>In case of acute overdose, patients should be managed by symptomatic and supportive care. There are no specific antidotes. Parecoxib is a prodrug of valdecoxib. Valdecoxib is not removed by haemodialysis. Diuresis or alkalisation of urine may not be useful due to high protein binding of valdecoxib.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, Coxibs, ATC code: M01AH04</p><p>&nbsp;</p><p>Parecoxib is a prodrug of valdecoxib. Valdecoxib is a selective COX‑2 inhibitor within the clinical dose range. Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX‑1 and COX-2, have been identified. COX‑2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception, and cognitive function). It may also play a role in ulcer healing. COX‑2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.</p><p><em>&nbsp;</em></p><p>The difference in antiplatelet activity between some COX‑1 inhibiting NSAIDs and COX‑2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX‑2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane. The clinical relevance of these observations has not been established.</p><p>&nbsp;</p><p>Parecoxib has been used in a range of major and minor surgeries. The efficacy of Dynastat was established in studies of dental, gynaecologic (hysterectomy), orthopaedic (knee and hip replacement), and coronary artery bypass graft surgical pain. The first perceptible analgesic effect occurred in 7‑13&nbsp;minutes, with clinically meaningful analgesia demonstrated in 23-39 minutes and a peak effect within 2&nbsp;hours following administration of single doses of 40&nbsp;mg IV or IM Dynastat. The magnitude of analgesic effect of the 40&nbsp;mg dose was comparable with that of ketorolac 60&nbsp;mg IM or ketorolac 30&nbsp;mg IV. After a single dose, the duration of analgesia was dose and clinical pain model dependent, and ranged from 6 to greater than 12 hours.</p><p>&nbsp;</p><p><u>Use of parecoxib beyond 3 days</u></p><p>Most trials were designed for dosing of parecoxib up to 3 days. Data from 3&nbsp;randomised placebo‑controlled trials, where the protocols allowed treatment of parecoxib for &gt;3&nbsp;days was pooled and analysed. In the pooled analysis of 676 patients, 318 received placebo and 358 received parecoxib. Of the patients treated with parecoxib, 317 patients received parecoxib for up to 4&nbsp;days, 32&nbsp;patients for up to 5 days, while only 8 patients were treated for up to 6 days and 1 patient for 7 or more days. Of the patients treated with placebo, 270 patients received placebo for up to 4&nbsp;days, 43&nbsp;patients for up to 5&nbsp;days, while only 3 patients were treated for up to 6 days and 2 patients for 7 or more days. Both groups had similar demographics. The mean (SD) duration of treatment was 4.1&nbsp;(0.4)&nbsp;days for parecoxib and 4.2 (0.5) days for placebo, the range was 4-7 days for parecoxib and 4‑9&nbsp;days for placebo. The occurrence of adverse events in patients receiving parecoxib for 4‑7&nbsp;days (median duration 4 days) was low after treatment Day 3 and similar to placebo.</p><p>&nbsp;</p><p><u>Opioid-sparing effects</u></p><p>In a placebo-controlled, orthopedic and general surgery study (n =1050), patients received Dynastat at an initial parenteral dose of 40&nbsp;mg IV followed by 20&nbsp;mg twice daily for a minimum of 72&nbsp;hours in addition to receiving standard care including supplemental patient controlled opioids. The reduction in opioid use with Dynastat treatment on Days 2 and 3 was 7.2&nbsp;mg and 2.8&nbsp;mg (37% and 28% respectively). This reduction in opioid use was accompanied by significant reductions in patient‑reported opioid symptom distress. Added pain relief compared to opioids alone was shown. Additional studies in other surgical settings provided similar observations. There are no data indicating less overall adverse events associated with the use of parecoxib compared to placebo when used in conjunction with opioids.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Gastrointestinal studies</u></p><p>In short-term studies (7 days), the incidence of endoscopically observed gastroduodenal ulcers or erosions in healthy young and elderly (&sup3; 65 years) subjects administered Dynastat (5-21%), although higher than placebo (5-12%), was statistically significantly lower than the incidence observed with NSAIDs (66-90%).</p><p>&nbsp;</p><p><u>CABG post-operative safety studies</u></p><p>In addition to routine adverse event reporting, pre-specified event categories, adjudicated by an independent expert committee, were examined in two placebo-controlled safety studies in which patients received parecoxib for at least 3 days and then were transitioned to oral valdecoxib for a total duration of 10-14 days. All patients received standard of care analgesia during treatment.</p><p>Patients received low-dose acetylsalicylic acid prior to randomization and throughout the two CABG surgery studies.</p><p>&nbsp;</p><p>The first CABG surgery study evaluated patients treated with IV parecoxib 40&nbsp;mg bid for a minimum of 3 days, followed by treatment with valdecoxib 40&nbsp;mg bid (parecoxib/valdecoxib group) (n=311) or placebo/placebo (n=151) in a 14-day, double-blind placebo-controlled study. Nine pre-specified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non‑infectious pulmonary complications, and death). There was a significantly (p&lt;0.05) greater incidence of cardiovascular/thromboembolic events (myocardial infarction, ischemia, cerebrovascular accident, deep vein thrombosis and pulmonary embolism) detected in the parecoxib/valdecoxib treatment group compared to the placebo/placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively). Surgical wound complications (most involving the sternal wound) were observed at an increased rate with parecoxib/valdecoxib treatment.</p><p><strong>&nbsp;</strong></p><p>In the second CABG surgery study, four pre-specified event categories were evaluated (cardiovascular/thromboembolic; renal dysfunction/renal failure; upper GI ulcer/bleeding; surgical wound complication). Patients were randomized within 24-hours post-CABG surgery to: parecoxib initial dose of 40&nbsp;mg IV, then 20&nbsp;mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20&nbsp;mg Q12H) (n=544) for the remainder of a 10 day treatment period; placebo IV followed by valdecoxib PO (n=544); or placebo IV followed by placebo PO (n=548). A significantly (p=0.033) greater incidence of events in the cardiovascular/thromboembolic category was detected in the parecoxib/valdecoxib treatment group (2.0%) compared to the placebo/placebo treatment group (0.5%). Placebo/valdecoxib treatment was also associated with a higher incidence of CV thromboembolic events versus placebo treatment, but this difference did not reach statistical significance. Three of the six cardiovascular thromboembolic events in the placebo/valdecoxib treatment group occurred during the placebo treatment period; these patients did not receive valdecoxib. Pre-specified events that occurred with the highest incidence in all three&nbsp;treatment groups involved the category of surgical wound complications, including deep surgical infections and sternal wound healing events.</p><p>&nbsp;</p><p>There were no significant differences between active treatments and placebo for any of the other pre‑specified event categories (renal dysfunction/failure, upper GI ulcer complications or surgical wound complications).</p><p>&nbsp;</p><p><u>General surgery</u></p><p>In a large (N=1050) major orthopaedic/general surgery trial, patients received an initial dose of parecoxib 40&nbsp;mg IV, then 20&nbsp;mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20&nbsp;mg Q12H) (n=525) for the remainder of a 10 day treatment period, or placebo IV followed by placebo PO (n=525). There were no significant differences in the overall safety profile, including the four pre-specified event categories described above for the second CABG surgery study, for parecoxib/valdecoxib compared to placebo treatment in these post-surgical patients.</p><p>&nbsp;</p><p><u>Platelet studies</u></p><p>In a series of small, multiple dose studies in healthy young and elderly subjects, parecoxib 20&nbsp;mg or 40&nbsp;mg twice daily had no effect on platelet aggregation or bleeding compared to placebo. In young subjects, parecoxib 40&nbsp;mg twice daily had no clinically significant effect on acetylsalicylic acid‑mediated inhibition of platelet function (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following IV or IM injection, parecoxib is rapidly converted to valdecoxib, the pharmacologically active substance, by enzymatic hydrolysis in the liver.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Exposure of valdecoxib following single doses of Dynastat, as measured by both the area under the plasma concentration vs. time curve (AUC) and peak concentration (C<sub>max</sub>), is approximately linear in the range of clinical doses. AUC and C<sub>max</sub> following twice daily administration is linear up to 50&nbsp;mg IV and 20&nbsp;mg IM. Steady state plasma concentrations of valdecoxib were reached within 4 days with twice daily dosing.</p><p>&nbsp;</p><p>Following single IV and IM doses of parecoxib 20&nbsp;mg, C<sub>max</sub> of valdecoxib is achieved in approximately 30 minutes and approximately 1 hour, respectively. Exposure to valdecoxib was similar in terms of AUC and C<sub>max</sub> following IV and IM administration. Exposure to parecoxib was similar after IV or IM administration in terms of AUC. Average C<sub>max</sub> of parecoxib after IM dosing was lower compared to bolus IV dosing, which is attributed to slower extravascular absorption after IM administration. These decreases were not considered clinically important since C<sub>max</sub> of valdecoxib is comparable after IM and IV parecoxib administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution of valdecoxib after its IV administration is approximately 55&nbsp;litres. Plasma protein binding is approximately 98% over the concentration range achieved with the highest recommended dose, 80&nbsp;mg/day. Valdecoxib, but not parecoxib, is extensively partitioned into erythrocytes.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Parecoxib is rapidly and almost completely converted to valdecoxib and propionic acid in vivo with a plasma half-life of approximately 22 minutes. Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulfonamide moiety. A hydroxylated metabolite of valdecoxib (via the CYP pathway) has been identified in human plasma that is active as a COX‑2 inhibitor. It represents approximately 10% of the concentration of valdecoxib; because of this metabolite&rsquo;s low concentration, it is not expected to contribute a significant clinical effect after administration of therapeutic doses of parecoxib.</p><p><strong>&nbsp;</strong></p><p><u>Elimination</u></p><p>Valdecoxib is eliminated via hepatic metabolism with less than 5% unchanged valdecoxib recovered in the urine. No unchanged parecoxib is detected in urine and only trace amounts in the faeces. About 70% of the dose is excreted in the urine as inactive metabolites. Plasma clearance (CL<sub>p</sub>) for valdecoxib is about 6&nbsp;l/hr. After IV or IM dosing of parecoxib, the elimination half-life (t<sub>1/2</sub>) of valdecoxib is about 8 hours.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Dynastat has been administered to 335 elderly patients (65-96 years of age) in pharmacokinetic and therapeutic trials. In healthy elderly subjects, the apparent oral clearance of valdecoxib was reduced, resulting in an approximately 40% higher plasma exposure of valdecoxib compared to healthy young subjects. When adjusted for body weight, steady state plasma exposure of valdecoxib was 16% higher in elderly females compared to elderly males (see section 4.2).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In patients with varying degrees of renal impairment administered 20&nbsp;mg IV Dynastat, parecoxib was rapidly cleared from plasma. Because renal elimination of valdecoxib is not important to its disposition, no changes in valdecoxib clearance were found even in patients with severe renal impairment or in patients undergoing dialysis (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Moderate hepatic impairment did not result in a reduced rate or extent of parecoxib conversion to valdecoxib. In patients with moderate hepatic impairment (Child-Pugh score 7-9), treatment should be initiated with half the usual recommended dose of Dynastat and the maximum daily dose should be reduced to 40&nbsp;mg since valdecoxib exposures were more than doubled (130%) in these patients. Patients with severe hepatic impairment have not been studied and therefore the use of Dynastat in patients with severe hepatic impairment is not recommended (see sections 4.2 and 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology or repeated dose toxicity at 2-fold the maximum human exposure to parecoxib. However, in the repeated dose toxicity studies in dogs and rats, the systemic exposures to valdecoxib (the active metabolite of parecoxib) were approximately 0.8-fold the systemic exposure in elderly human subjects at the maximum recommended therapeutic dose of 80&nbsp;mg daily. Higher doses were associated with aggravation and delayed healing of skin infections, an effect probably associated with COX-2 inhibition.</p><p>&nbsp;</p><p>In reproduction toxicity tests, the incidence of post-implantation losses, resorptions and foetal body weight retardation occurred at doses not producing maternal toxicity in the rabbit studies. No effects of parecoxib on male or female fertilities were found in rats.</p><p>&nbsp;</p><p>The effects of parecoxib have not been evaluated in late pregnancy or in the pre- and postnatal period.</p><p>&nbsp;</p><p>Parecoxib administered intravenously to lactating rats as a single dose showed concentrations of parecoxib, valdecoxib and a valdecoxib active metabolite in milk similar to that of maternal plasma.</p><p>&nbsp;</p><p>The carcinogenic potential of parecoxib has not been evaluated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Disodium hydrogen phosphate</p><p>Phosphoric acid and/or sodium hydroxide (for pH adjustment).</p><p>&nbsp;</p><p><u>Solvent</u></p><p>Sodium chloride</p><p>Hydrochloric acid or sodium hydroxide (for pH adjustment)</p><p>Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except for those mentioned in section 6.6.</p><p>&nbsp;</p><p>Dynastat and opioids should not be administered together in the same syringe.</p><p>&nbsp;</p><p>Use of Ringer-Lactate solution for injection or glucose 50&nbsp;mg/ml (5%) in Ringer Lactate solution for injection for reconstitution will cause the parecoxib to precipitate from solution and therefore is <strong>not</strong> recommended.</p><p>&nbsp;</p><p>Use of water for injection is <strong>not</strong> recommended, as the resulting solution is not isotonic.</p><p>&nbsp;</p><p>Dynastat should not be injected into an IV line delivering any other medicinal product. The IV line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility (see section 6.6).</p><p>&nbsp;</p><p>Injection into an IV line delivering glucose 50&nbsp;mg/ml (5%) in Ringer-Lactate solution for injection, or other IV fluids not listed in section 6.6, is not recommended as this may cause precipitation from solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
The shelf life of the un-reconstituted product is 3 years.

Chemical and physical in-use stability of the reconstituted solution, which should not be refrigerated or frozen, have been demonstrated for up to 24 hours at 25C. Thus, 24 hours should be considered the maximum shelf life of the reconstituted product. However, due to the importance of microbiological infection risk for injectable products, the reconstituted solution should be used immediately unless reconstitution has taken place in controlled and validated aseptic conditions. Unless such requirements are met, in-storage times and conditions prior to use are the responsibility of the user, and would not normally be longer than 12 hours at 25C.




            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C ,Do not refrigerate or Freeze.</p><p>For storage conditions of the reconstituted medicinal product see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I colourless glass vials (5 ml) with a butyl rubber stopper, sealed with a purple polypropylene flip-off cap on the aluminium overseal.</p><p>&nbsp;</p><p>Dynastat is available in packs containing 10 vials.</p><p><strong>&nbsp;</strong></p><p><strong>40 mg powder and solvent for solution for injection:</strong></p><p><em>&nbsp;</em></p><p><u>Parecoxib sodium vials</u></p><p>Type I colourless glass vials (5 ml) with a laminated butyl rubber stopper, sealed with a purple polypropylene flip-off cap on the aluminium overseal.</p><p>&nbsp;</p><p><u>Solvent ampoules</u></p><p>2&nbsp;ml ampoule: colourless neutral glass, Type I.</p><p>&nbsp;</p><p>Dynastat is supplied as a sterile, single unit-of-use vial that is packaged with a 2&nbsp;ml ampoule with a fill volume of 2&nbsp;ml sodium chloride 9&nbsp;mg/ml (0.9%) solution (see below for various pack sizes and configurations)</p><p>&nbsp;</p><p><u>Pack sizes</u></p><p>5 + 5 pack: contains 5 powder vials and 5 solvent ampoules.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Dynastat must be reconstituted before use. It is preservative free. Aseptic technique is required for its preparation.</p><p>&nbsp;</p><p><u>Reconstitution solvents</u></p><p>Reconstitute &nbsp;40&nbsp;mg of Dynastat with 2&nbsp;ml sodium chloride 9&nbsp;mg/ml (0.9%) solution.</p><p>&nbsp;</p><p>The <strong>only</strong> other acceptable solvents for reconstitution are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucose 50&nbsp;mg/ml (5%) solution for infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium chloride 4.5&nbsp;mg/ml (0.45%) and glucose 50&nbsp;mg/ml (5%) solution for injection/infusion</p><p>&nbsp;</p><p><u>Reconstitution process</u></p><p>Use aseptic technique to reconstitute lyophilised parecoxib (as parecoxib).</p><p>Remove the purple flip-off cap to expose the central portion of the rubber stopper of the 40&nbsp;mg parecoxib vial. Withdraw, with a sterile needle and syringe, 2&nbsp;ml of an acceptable solvent and insert the needle through the central portion of the rubber stopper transferring the solvent into the 40&nbsp;mg vial. Dissolve the powder completely using a gentle swirling motion and inspect the reconstituted product before use. The entire contents of the vial should be withdrawn for a single administration.</p><p>&nbsp;</p><p>After reconstitution, the liquid should be a clear solution. It should be inspected visually for particulate matter and discoloration prior to administration. The solution should not be used if discolored or cloudy, or if particulate matter is observed. Dynastat should be administered within 24&nbsp;hours of reconstitution (see section 6.3), or discarded.</p><p>&nbsp;</p><p>The reconstituted product is isotonic.</p><p>&nbsp;</p><p><u>IV line solution compatibility</u></p><p>After reconstitution with acceptable solvents, Dynastat may <strong>only</strong> be injected IV or IM, or into IV lines delivering:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection/infusion;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucose 50&nbsp;mg/ml (5%) solution for infusion;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium chloride 4.5&nbsp;mg/ml (0.45%) and glucose 50&nbsp;mg/ml (5%) solution for injection/infusion;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringer-Lactate solution for injection.</p><p>&nbsp;</p><p>For single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>&nbsp;</strong></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles, Belgium

MANUFACTURING AND PRIMARY PACKAGING SITE:
Pharmacia & Upjohn Company LLC
Kalamazoo, USA

SECONDARY PACKAGING AND RELEASE SITE:
Pfizer Manufacturing Belgium NV, Puurs-Sint-Amands, Belgium.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2025
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>